Higher US reimbursement for VADs (ventricular assist devices):
This article was originally published in Clinica
The US Centers for Medicare & Medicaid Services (CMS) has recommended the establishment of a new diagnosis related group to cover inpatient ventricular assist device procedures. The proposal, if approved, could mean a 40% rise in reimbursement for the procedure, from the current $38,000 to $53,000, notes Thoratec, the Pleasanton, California developer of the Heartmate left ventricular assist system. The new rule and payment level would take effect on October 1 2002.
You may also be interested in...
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.